

Appendix S1.

Search strategy for the systematic literature search

For observational studies

- # 1 Dermatitis, Atopic/
- # 2 atopic dermatitis.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
- # 3 Eczema/
- # 4 eczema.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
- # 5 1 or 2 or 3 or 4
- # 6 epidemiologic studies/ or exp case-control studies/ or exp cohort studies/ or exp seroepidemiologic studies/ (epidem: adj stud:).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
- # 7 6 or 7
- # 9 5 and 8
- # 10 exp Hypersensitivity, Immediate/
- # 11 Allergens/
- # 12 Skin Tests/
- # 13 Hypersensitivity/
- # 14 prick.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
- # 15 exp Immunoglobulin E/
- # 16 immunoglobulin E.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
- # 17 IgE.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
- # 18 Genotype/
- # 19 Genetic Heterogeneity/
- # 20 Hygiene Hypothesis/
- # 21 Animals, Domestic/
- # 22 Cats/
- # 23 Dogs/
- # 24 Avoidance Learning/
- # 25 Administration, Topical/
- # 26 Intermediate Filament Proteins/df, ge [Deficiency, Genetics]

- # 27 Therapeutics/mt, ut [Methods, Utilization]
- # 28 Pharmaceutical Preparations/ad, de [Administration & Dosage, Drug Effects]
- # 29 Adrenal Cortex Hormones/dt, tu [Drug Therapy, Therapeutic Use]
- # 30 Androstadienes/tu [Therapeutic Use]
- # 31 Calcineurin/ai [Antagonists & Inhibitors]
- # 32 Dermatologic Agents/tu [Therapeutic Use]
- # 33 Immunosuppressive Agents/tu [Therapeutic Use]
- # 34 Methylprednisolone/aa, tu [Analogues & Derivatives, Therapeutic Use]
- # 35 Tacrolimus/tu [Therapeutic Use]
- # 36 allerg: mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (142303)
- # 37 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
- # 38 9 and 37
- # 39 limit 38 to humans
- # 40 limit 39 to (english or german)
- # 41 limit 41 to abstracts

For RCT

- # 1 randomized controlled trial.pt.
- # 2 controlled clinical trial.pt.
- # 3 randomized.ab.
- # 4 randomly.ab.
- # 5 placebo.ab.
- # 6 trial.ti.
- # 7 clinical trials as topic.sh.
- # 8 1 or 2 or 3 or 4 or 5 or 6 or 7
- # 9 humans.sh.
- # 10 exp Animals/
- # 11 10 not 9
- # 12 8 not 11
- # 13 Dermatitis, Atopic/
- # 14 atopic dermatitis.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
- # 15 13 or 14
- # 16 Eczema/
- # 17 eczema.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
- # 18 16 or 17
- # 19 15 or 18
- # 20 12 and 19